Skip Navigation



JAC Advance Access published online on September 19, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl385
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/5/1031    most recent
dkl385v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shi, M.
Right arrow Articles by Xu, Y. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, M.
Right arrow Articles by Xu, Y. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received April 23, 2006
Revised August 16, 2006
Accepted August 30, 2006

Original article

Sequential treatment with lamivudine and interferon-{alpha} monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations

Ming Shi 1, Rong Sheng Wang 2, Hua Zhang 2, Yu Fen Zhu 2, Bei Han 2, Yong Zhang 3, Li Ji Jin 4, Zhi-Jun Yang 5, and Yong Ping Xu 4 *

1 Department of Biotechnology, Dalian University of Technology, Dalian 116023, Liaoning Province, China; No. 6 Hospital of Dalian, Dalian 116001, Liaoning Province, China
2 Jiangsu Oil Field Hospital, Shaobo, Jiangdu 225261, Jiangsu Province, China
3 No. 6 Hospital of Dalian, Dalian 116001, Liaoning Province, China
4 Department of Biotechnology, Dalian University of Technology, Dalian 116023, Liaoning Province, China
5 Management School, Shanghai Jiaotong University, Shanghai, China

* To whom correspondence should be addressed.
Yong Ping Xu, E-mail: zhsh6655{at}sohu.com


  Abstract

Objectives: To assess the efficacy of sequential treatment with lamivudine and interferon-{alpha} monotherapies in Chinese patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.

Methods: One hundred and sixty-two patients with HBeAg-negative chronic hepatitis B were included in this study. Ninety-eight were treated with lamivudine alone (100 mg per day) for 48 weeks (group B). Sixty-four were treated with lamivudine alone (100 mg per day) for 20 weeks, then combined with interferon-{alpha}-2b (5 million units three times per week) for 4 weeks and then treated for another 24 weeks with interferon-{alpha}-2b alone (5 million units three times per week) (group A). All patients were followed for an additional 24 weeks.

Results: After 48 weeks of treatment, the percentage of patients with normalization of alanine aminotransferase (ALT) levels or hepatitis B virus (HBV) DNA levels below 1000 copies/mL was not significantly different between the lamivudine monotherapy group (55.10% and 55.10%, respectively) and the sequential treatment group (59.36% and 56.25%, respectively). The percentage of patients with normalized ALT levels was significantly higher in group A (53%) than in group B (36%) at week 72 (P < 0.05). The percentage of patients with lamivudine-resistant mutations was significantly higher with lamivudine monotherapy (22.45%) than with sequential therapy (P < 0.05).

Conclusions: Sequential treatment of chronic hepatitis B with lamivudine and interferon-{alpha} monotherapies is as effective as lamivudine-alone treatment in Chinese patients. However, sequential treatment can significantly suppress the emergence of lamivudine-resistant mutations.

Keywords: chronic hepatitis B; hepatitis B virus; HBV; YMDD.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
T. A. Shamliyan, R. MacDonald, A. Shaukat, B. C. Taylor, J.-M. Yuan, J. R. Johnson, J. Tacklind, I. Rutks, R. L. Kane, and T. J. Wilt
Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference
Ann Intern Med, January 20, 2009; 150(2): 111 - 124.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.